Mentions
Extended reach
Total likes
Video views
AI synopsis
Numerous conversations critique the claims of aducanumab's efficacy, with users emphasizing the unanimous vote against its approval by an independent FDA advisory board and citing phrases like 'no evidence was presented to correlate biomarker changes to cognitive benefits.' The tone is often sharp and accusatory, with terms like 'lies' used to describe the approval process, indicating a strong emotional response to the perceived misrepresentation of the drug's benefits.
Many discussions highlight strong disagreement with the efficacy claims of aducanumab, emphasizing the disconnect between Biogen's assertions and independent analyses.
While there is some curiosity about the drug's implications, the overwhelming sentiment leans towards skepticism.
Participants engage in nuanced debate about the trial results, but many express frustration or confusion rather than deep involvement.
Users believe the findings significantly affect perceptions of FDA approval processes and pharmaceutical accountability.
Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four months ago: https://t.co/KNhV22L3vw Special thanks to @E_Barratt, @alexiswrites, @ScienceFred, and @ceriley for their work on those episodes.
Uma parte substancial da comunidade científica segue apreensiva e sugerindo a necessidade de um novo ensaio clínico de fase III (vale a pena ler aqui
Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devastating disease. #ENDALZ See our dispassionate assessment of the data in this perspective: “Failure to demonstrate efficacy of aducanumab” https://t.co/CSWR7PB1yO
Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheimer´s & Dementia
Clinical trial aficionados — I *highly* recommend this detailed analysis of aducanumab studies (open access). It’s one of the best case studies of study design & interpretation I’ve seen. https://t.co/AYSj1QusdX
@hirosetakao 薬剤師の立場から言うと、この手の分野の薬は微妙です。エーザイのも（たぶん）ダメだと思います。 https://t.co/jqNKoO3kqn https://t.co/miKcMTNaOZ
In 2021, the FDA approved Aducanumab, claiming it stops Alzheimer's by removing brain plaques. However, the trials produced mixed results, leaving its efficacy unclear. This video delves into these complexities and…
This recording discusses the current therapeutics landscape in Alzheimer's Disease (AD) and examines the debate around targeting amyloid. The analysis highlights the mixed results of aducanumab's trials, arguing for…
Meanwhile, independent researchers weren’t buying it and the 10 member independent FDA advisory board voted unanimously not to approve the drug (9 against, 1 neutral) https://t.co/T1MtBzCEU3 https://t.co/quEmgHVWR5
RT @LogarithmicDis: $BIIB playbook: abandon both aduhelm P3’s for futility, do some post hoc analyses to change futile to effective, then a…
@DanClintonRN You are confusing diagnosing people with AD with effectiveness of amyloid removal therapies. https://t.co/aO0dja3WhX
@FDA_Drug_Info Example: Aducanumab Meds require efficacy for approval: https://t.co/DBUkL5YPBa Fda Approval: https://t.co/youpowm3t5 Lacks efficacy: https://t.co/nLHCKMQFJV THIS is "Accelerated Approval" aka LIES https://t.co/O0HUrV0UR9
RT @DavidJonesBrain: @DanClintonRN @nvillain_alz @LonSchneiderMD @AlbertoEspay @Kariem_Ezzat @pash22 @smead2 @MadhavThambiset @ProfRobHowar…
@DanClintonRN @nvillain_alz @LonSchneiderMD @AlbertoEspay @Kariem_Ezzat @pash22 @smead2 @MadhavThambiset @ProfRobHoward @matthewherper @DrTFromKC @seb_walsh @PhilAlz @JosephTherr @dmrind @Scott_M_Reid @EWidera @RenegadeSynapse @gregggonsalves @LogarithmicDis @KasperKepp @Jennife10651535 @pxrobbo @MemoryDoc @metapredict @CorriveauNick @eturnermd1 @kateeeemily @StefanoSensi14 @VincentPlanche @ayton_scott @reshmagar @KarlHerrup @GiovanniFrisoni @macesari @geoperry @samgandy @Gill_Livingston @andrea_sturchio @AndaloussiLab @rkhamsi @r_merrick @schrag_matthew @kathy_y_liu @naomikresge @MedicareGov @JAMANetwork @ManlyEpic @KcD_PhD I knew about the phase 2 so the phase 3 was not a surprise. Why would that change my views? What do you think my views are that should have been changed? Here were our views of aducanumab at the time: https://t.co/v2DdLl2Iyp
RT @DavidJonesBrain: @DanClintonRN @nvillain_alz @LonSchneiderMD @AlbertoEspay @Kariem_Ezzat @pash22 @smead2 @MadhavThambiset @ProfRobHowar…
@DanClintonRN @nvillain_alz @LonSchneiderMD @AlbertoEspay @Kariem_Ezzat @pash22 @smead2 @MadhavThambiset @ProfRobHoward @matthewherper @DrTFromKC @seb_walsh @PhilAlz @JosephTherr @dmrind @Scott_M_Reid @EWidera @RenegadeSynapse @gregggonsalves @LogarithmicDis @KasperKepp @Jennife10651535 @pxrobbo @MemoryDoc @metapredict @CorriveauNick @eturnermd1 @kateeeemily @StefanoSensi14 @VincentPlanche @ayton_scott @reshmagar @KarlHerrup @GiovanniFrisoni @macesari @geoperry @samgandy @Gill_Livingston @andrea_sturchio @AndaloussiLab @rkhamsi @r_merrick @schrag_matthew @kathy_y_liu @naomikresge @MedicareGov @JAMANetwork @ManlyEpic @KcD_PhD @DanClintonRN you may find this lecture helpful: https://t.co/x8x1ApOANc
@DrTFromKC @dcweisman @nvillain_alz @MemoryDoc @dmrind @LonSchneiderMD @pash22 @MadhavThambiset @ChuckGartland1 @eturnermd1 @kateeeemily @gregggonsalves @AlbertoEspay @PhilAlz @StefanoSensi14 @JosephTherr @VincentPlanche @AE_MD @ProfRobHoward @seb_walsh @ayton_scott @reshmagar @jasonkarlawish @KarlHerrup @GiovanniFrisoni @macesari @geoperry @samgandy @Gill_Livingston @Kariem_Ezzat @andrea_sturchio @AndaloussiLab @rkhamsi @r_merrick @DrLiHueiTsai @adamfeuerstein @Jasonmmast @damiangarde @lauriemcginley2 @grace_huckins @aylinsdincer @PamBelluck @schrag_matthew @kathy_y_liu @naomikresge @congressdotgov @CMSGov @LizCoulthard @sadneurons @DavidJonesBrain https://t.co/wbPqDYjJfo
@dcweisman @MaTeFerretti Clearly explained here @dcweisman https://t.co/x8x1ApOANc
RT @DavidJonesBrain: @NicoleCRust @jasonkarlawish I have a track record of cautious skepticism here (see below article on aducanumab). This…
RT @DavidJonesBrain: Prob a good time to re-post this short lecture for people interested in contextualizing the transformative lecanemab…
RT @DavidJonesBrain: Prob a good time to re-post this short lecture for people interested in contextualizing the transformative lecanemab…
Prob a good time to re-post this short lecture for people interested in contextualizing the transformative lecanemab results: https://t.co/x8x1ApOANc
@NicoleCRust @jasonkarlawish I have a track record of cautious skepticism here (see below article on aducanumab). This trial will change clinical practice and reshape the field! https://t.co/v2DdLkL79P
@Marlou_La It is a bit controversial with pros and cons https://t.co/k9FUvAGC66
RT @SciShow: You may have seen some recent news and have questions about Alzheimer's and amyloid-targeting drugs. Here's a primer on some o…
RT @SciShow: You may have seen some recent news and have questions about Alzheimer's and amyloid-targeting drugs. Here's a primer on some o…
RT @SciShow: You may have seen some recent news and have questions about Alzheimer's and amyloid-targeting drugs. Here's a primer on some o…
You may have seen some recent news and have questions about Alzheimer's and amyloid-targeting drugs. Here's a primer on some of this research: https://t.co/1CNhSuHCy9 https://t.co/JlPMDKml57
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
@AranJaeger ggf das hier von vor 4 Monaten https://t.co/8Ep8iMrToW
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
RT @hankgreen: Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four mo…
Very proud of the SciShow team for putting together this video four years ago: https://t.co/MtsAfPOj8q And this one four months ago: https://t.co/KNhV22L3vw Special thanks to @E_Barratt, @alexiswrites, @ScienceFred, and @ceriley for their work on those episodes.
RT @Frank_S_David: Clinical trial aficionados — I *highly* recommend this detailed analysis of aducanumab studies (open access). It’s one o…
RT @Frank_S_David: Clinical trial aficionados — I *highly* recommend this detailed analysis of aducanumab studies (open access). It’s one o…
RT @Frank_S_David: Clinical trial aficionados — I *highly* recommend this detailed analysis of aducanumab studies (open access). It’s one o…
Clinical trial aficionados — I *highly* recommend this detailed analysis of aducanumab studies (open access). It’s one of the best case studies of study design & interpretation I’ve seen. https://t.co/AYSj1QusdX
@AlbertoEspay My thoughts are clearly explained in this short video: https://t.co/x8x1Aq6bEK
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/ld7EGAkyAq via @YouTube
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/eMzmRkNSLv
RT @DavidJonesBrain: There remains confusion about what MCI is, but does that mean we need to return to 1984? I think there are more produ…
There remains confusion about what MCI is, but does that mean we need to return to 1984? I think there are more productive paths ... https://t.co/x8x1ApOANc https://t.co/I5TBETznll https://t.co/5KlrfElFeU
@alexandrosM This is somewhat similar - aducanumab, approved last year for AlzDis, stopped the 2 parallel Ph 3 studies for futility… final analysis a few mo later resulted in success in 1 study & semi-success in the other, and later the approval https://t.co/itl4tTaarb 1/2
Lets go a little deeper into the rabbit hole. Just a little. https://t.co/AGzFm6h96D
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/OEA0FTk7U1 via @YouTube #scishow
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/R9c6QwqU2Q via @YouTube
https://t.co/i9e9Elgwoq @jimmy_dore
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/XXQ9pa47TO via @YouTube
( ¯−¯ ) ﾌｰﾑ correlation or causation? USA FDA approves but EU not. "An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s?" on YouTube - https://t.co/3TiAjkTjQx
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/nBImiupw0T via @YouTube
https://t.co/adOCQHJW8y
RT @SciShow: The new Alzheimer’s drug that... doesn’t treat Alzheimer’s? https://t.co/DtctJwyr5D https://t.co/GZrclSTW4x
The new Alzheimer’s drug that... doesn’t treat Alzheimer’s? https://t.co/DtctJwyr5D https://t.co/GZrclSTW4x
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/chMhruD5C3
Here's the other @SciShow episode that kept me so busy last month! It's on the aducanumab drama, and what comes next for Alz drug research Shout out to @neva9257, @rocza and Alex Billow for working with me on this, and the rest of the team for being stars https://t.co/O2aybBczvN
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/qSee3NKsSL via @YouTube
Ternyata Alzheimer lebi kompleks dari yang diajarin di kelas https://t.co/D5GYcG2Rqe
https://t.co/XGFI6qUu1A
An Alzheimer’s Drug That Doesn’t Treat Alzheimer’s? https://t.co/3IlbMNHWBx via @YouTube
@khalidensophie Een goede uitleg in de SciShow vandaag https://t.co/fQHMKzGSGa
An Alzheimer's drug that doesn't treat Alzheimer's? https://t.co/AjDqMDlgWA https://t.co/BPHUA8fecr
New video by SciShow: An Alzheimer's drug that doesn't treat Alzheimer's? https://t.co/30pWbZcGCj
An Alzheimer's drug that doesn't treat Alzheimer's? https://t.co/sMMy2bDkrc via @YouTube
$BIIB playbook: abandon both aduhelm P3’s for futility, do some post hoc analyses to change futile to effective, then apply for approval. Heavily fund @alzassociation and have them beat the PR war drums against CMS decision. Best summary article in 2020: https://t.co/PxbTyTQRcO
Glad to see more literature, but there has been little scientific discourse about this data in the literature and one needs to consider why this happened. We felt compelled to start a discourse in the scientific literature and wrote this years ago: https://t.co/CSWR7PB1yO https://t.co/pqQRdB7IXz
Should amyloid be targeted in Alzheimer's disease? https://t.co/EiaEGHTilt via @YouTube
RT @DavidJonesBrain: @bryanneth @Brain1878 @j_graffradford @prashvemuri @vijaykramanan @fishTMH Thoughts on related additions to A/T/N http…
@KordingLab In fact, I use the word cause many times trying to answer this question if you are interested: https://t.co/x8x1ApOANc
@bryanneth @Brain1878 @j_graffradford @prashvemuri @vijaykramanan @fishTMH Thoughts on related additions to A/T/N https://t.co/x8x1ApOANc
No case for efficacy of Aducanumab based on the clinical trial data that @Biogen has made publicly available. https://t.co/rCHYoXLiFV via @MayoClinicNeuro 's #DavidKnopman & @DavidJonesBrain & @StanfordMed 's #MichaelGreicius
RT @matsuikentaro1: そもそも、「ベンゾジアゼピンがアミロイド蓄積と海馬の萎縮を阻害する」が正しかったとして、それが認知症の予防に寄与するかどうか？ このへんはaducanumabをめぐる議論が有名です（アミロイドの減少は必ずしも認知機能の改善をもたらさない？…
RT @matsuikentaro1: そもそも、「ベンゾジアゼピンがアミロイド蓄積と海馬の萎縮を阻害する」が正しかったとして、それが認知症の予防に寄与するかどうか？ このへんはaducanumabをめぐる議論が有名です（アミロイドの減少は必ずしも認知機能の改善をもたらさない？…
RT @matsuikentaro1: そもそも、「ベンゾジアゼピンがアミロイド蓄積と海馬の萎縮を阻害する」が正しかったとして、それが認知症の予防に寄与するかどうか？ このへんはaducanumabをめぐる議論が有名です（アミロイドの減少は必ずしも認知機能の改善をもたらさない？…
そもそも、「ベンゾジアゼピンがアミロイド蓄積と海馬の萎縮を阻害する」が正しかったとして、それが認知症の予防に寄与するかどうか？ このへんはaducanumabをめぐる議論が有名です（アミロイドの減少は必ずしも認知機能の改善をもたらさない？） https://t.co/nIamZdueaW
@technoslerphile @AlbertoEspay Independent analysis of the results Biogen did release have been less than flattering https://t.co/GgWmsgTnn8
Source: https://t.co/E3auqEaycQ
why aducanumab is getting so much flak. see for youself. “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019” https://t.co/nEQLsA6l1x.
I think this article on aducanumab should go another round. https://t.co/zLU0CTEcIL
@specterm @NewYorker You missed this important argument by Knopman: "The key point is this: The larger decline in the placebo group in EMERGE is an alternative explanation for statistically significant benefits for high-dose ADU in that trial." https://t.co/I2aZYxraH6
It was approved based on two phase III trials from 2019. This drug was shown to have a statistically significant effect on biomarkers and plaque buildup. However, there is little to no correlation on actual cognitive benefits. https://t.co/2QiwkFwZ9T https://t.co/h5dEaQ4iJz
バイオジェンが2019年12月に報告したEMERGEおよびENGAGE試験の分析 https://t.co/HGMhcKw7EW で、論文見つけられなかった(´;ω;｀) でも結果は見つけた https://t.co/QW3WdZgUpk
FDA's decision does have me a bit confused - last thing I heard was that @biogenms pulled the plug on its #Aducanumab trials based on futility analyses? - see https://t.co/5H0UOwxqtq Keen to hear thoughts of others in the #Alzheimers #Dementia #amyloid field e.g. @AmyBrodtmann https://t.co/HhdaBW8ciI
aducanumabの承認に湧いているけれど、MMSEで3点程度だと費用対効果については悲しいものと言わざるを得ない 栄光への素晴らしい一歩になることを期待してるけど、、、 https://t.co/G8JjTTZQSx
It's only in the future that we'll be able to clearly see the effects of Aducanumab. There is no way to compare whether or not it has reduced the progression of Alzheimer's in the same person, so FDA's decision is reasonable. https://t.co/aHW3NarYgt https://t.co/OfI2UDeDtz
@hirosetakao 薬剤師の立場から言うと、この手の分野の薬は微妙です。エーザイのも（たぶん）ダメだと思います。 https://t.co/jqNKoO3kqn https://t.co/miKcMTNaOZ
RT @virgilioh:
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 https://t.co/lVq5ZoMY8p
https://t.co/DnM7mQrnrh
@FreeSpeechHK 隻藥曾經係2019年終止過臨床實驗，因為結果比用placebo更差。 一年藥費盛惠5萬6美金，而且只對早期患者有效。 而家藥廠惡晒，FDA屁都唔敢放一個，睇定啲先啦 https://t.co/VgbPGZ4hhL
@LuisCLCorreia @US_FDA @wagnersbrum @jpfsouza33 @alzforum Alguns resultados podem ser vistos aqui também
RT @syuichiao89: no evidence was presented to correlate biomarker changes to cognitive benefits. エーザイ、マジで空売りの餌食になるで
"La FDA aprueba medicamento contra el Alzheimer por primera vez en 20 años". Claro ejemplo de la mi3rda que es la industria farmacéutica. En 2019, el fabricante, Biogen, suspendió su ensayo clínico antes de concluir por falta de evidencia de mejoría clín… https://t.co/DFNSXrmvqT https://t.co/0UrALUbyxY
RT @Alzhacker: https://t.co/fbkESYBVdL アデュカヌマブの有効性を示せず バイオジェン社が報告したEMERGE試験およびENGAGE試験の分析 2019年12月 バイオマーカーのデータは標的への関与と一致していたが、バイオマーカーの変化と認…
@Cur4E7Iox5S0mOR https://t.co/KtV9r4NQGj
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, D… https://t.co/8IL1jOEYOK
no evidence was presented to correlate biomarker changes to cognitive benefits. エーザイ、マジで空売りの餌食になるで
aducanumab、承認されたんですね。 効果は認められなかったから、開発中止で申請取下になったと思い込んでた… 素人だから、Tau仮説を支持する研究増えてるかと思ったけど、β amyloid仮説が再評価されたりするんかな？ https://t.co/5L0EhcxxXg
Though Aducanumab was effective in reducing Amyloid based on imaging, the clinical benefit is unclear. ENGAGE was actually in the wrong direction for cognitive decline with the high-dose. https://t.co/Uv49nObGEW
RT @Vadeboncoeur_Al: 2/ Autre texte fort critique par rapport à l'efficacité prétendue du médicament. https://t.co/lj5i3dkfMc
2/ Autre texte fort critique par rapport à l'efficacité prétendue du médicament. https://t.co/lj5i3dkfMc
https://t.co/xqvbqkk3Am メッチャこきおろしてんね
RT @Alzhacker: https://t.co/fbkESYBVdL アデュカヌマブの有効性を示せず バイオジェン社が報告したEMERGE試験およびENGAGE試験の分析 2019年12月 バイオマーカーのデータは標的への関与と一致していたが、バイオマーカーの変化と認…
RT @Alzhacker: https://t.co/fbkESYBVdL アデュカヌマブの有効性を示せず バイオジェン社が報告したEMERGE試験およびENGAGE試験の分析 2019年12月 バイオマーカーのデータは標的への関与と一致していたが、バイオマーカーの変化と認…
Interesting... I'm not the only one who wasn't expecting this: https://t.co/firgQtbQ5Z Decision seems to be based on fairly weak data - post hoc analysis of a "failed" Phase 3 - and the company will have to run a new trial for robust data. Hopefully they can confirm efficacy https://t.co/0Ybp9tOPL3 https://t.co/6jjfOz1fMu
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 https://t.co/960tYlE1K1 #aducanumab
https://t.co/fbkESYBVdL アデュカヌマブの有効性を示せず バイオジェン社が報告したEMERGE試験およびENGAGE試験の分析 2019年12月 バイオマーカーのデータは標的への関与と一致していたが、バイオマーカーの変化と認知機能の改善とを関連付ける証拠は示されなかった。
Men enl tidningsartikeln nov 2020 (tydligen från USA:s Alzheimerspatientförening) "Based on our review of data presented publicly in December 2019, we do not agree with Biogen's claim for efficacy of ADU" https://t.co/syyAQHjTZ5
Artikel nov 2020 "Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen. .One trial was trending positive .while the other showed no benefits from aducanumab" https://t.co/syyAQHjTZ5
503/ #Alzheimers I was disappointed to read this today. I had hoped to start this drug this month for my AZ. https://t.co/f2F2KvWkFd https://t.co/a5I55OxiQc
@AnilMakam @geri_doc @alzassociation What I want to know is how did @alzassociation decide to advocate for aducanumab. Did they involve researchers in their org to decide? At least 1 of their Medical and Scientific Advisory Group (MSAG), David Knopman, gave it a big no here https://t.co/BC3gBLRS1A #endalz #moretime https://t.co/53mpnIXE7r
#OpenAccess in Alzheimer's & Dementia: Failure to demonstrate efficacy of #aducanumab. This analysis of the EMERGE & ENGAGE trials reported by Biogen supports the conduct of a third, phase III trial with high‐dose aducanumab. ➡️ https://t.co/iMAcK20Ddb @alzdemjournals @ISTAART https://t.co/9yTPOnmcFX
Se retoman los ensayos ENGAGE y EMERGE, previamente desestimados, para demostrar la eficacia de aducanumab en #Alzheimer temprano. ¿ Qué ha cambiado? https://t.co/pp0fjhCmVv
Great perspective by my collaborator David Knopman! Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 https://t.co/J1v4X27W6K
No demuestra eficacia https://t.co/Zkkdp0G7kv
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
FDA承認直前?の #aducanumab に、Mayo/Stanfordから異議ペーパー。事後サブグループ分析結果では、バイオマーカー変化と認知機能改善の関連が不明、supports the conduct of a third, definitive phase III、と。#Remdesivir の直前先行例から、FDAの前のめりは明らか。 https://t.co/bbujl4ltQq
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @erzimmer: Uma parte substancial da comunidade científica segue apreensiva e sugerindo a necessidade de um novo ensaio clínico de fase I…
RT @erzimmer: Uma parte substancial da comunidade científica segue apreensiva e sugerindo a necessidade de um novo ensaio clínico de fase I…
@mfwork @TheLancetNeuro Eu vou na linha do artigo que citei ali em cima (https://t.co/OyazJC902y). Acredito que um novo ensaio clínico de fase III com a dose mais alta seja o mais indicado.
RT @erzimmer: Uma parte substancial da comunidade científica segue apreensiva e sugerindo a necessidade de um novo ensaio clínico de fase I…
Uma parte substancial da comunidade científica segue apreensiva e sugerindo a necessidade de um novo ensaio clínico de fase III (vale a pena ler aqui
@smead2 https://t.co/1dFmyljivh
@ZivGanOr The trial investigators themselves don't think this should be approved... https://t.co/ij7WEsyTAo
@smead2 What do you think about what the trial investigators wrote? https://t.co/ij7WEsyTAo
RT @PabloRichly: Esta semana es importante para las demencias. Una aprobación solo beneficiaría a la industria. https://t.co/5jHk6HQ1fC
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
#Alzheimers Marketing Aut. Application #EMA_News for #Biogen #Aducanumab for MCI due to #AD Aducanumab's efficacy as a treatment for the cognitive dysfunction in Alzheimer's disease cannot be proved by clinical trials with divergent outcomes https://t.co/MYDgkcoxTG
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @danisevisan: Failure to demonstrate efficacy of aducanumab in Alzheimer: An analysis of the EMERGE and ENGAGE trials as reported by Bio…
Failure to demonstrate efficacy of aducanumab in Alzheimer: An analysis of the EMERGE and ENGAGE trials as reported by Biogen https://t.co/BMhB81anb9
RT @PabloRichly: Esta semana es importante para las demencias. Una aprobación solo beneficiaría a la industria. https://t.co/5jHk6HQ1fC htt…
Esta semana es importante para las demencias. Una aprobación solo beneficiaría a la industria. https://t.co/5jHk6HQ1fC https://t.co/hSVURgWDJN
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 https://t.co/VPGfPJmZtD
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMRGE and ENGAGE Trials as reported by Biogen December 2019” - Sabbagh - - Alzheimer's & Dementia - Wiley Online Library https://t.co/vhO4GJLcJ9
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 - Knopman - - Alzheimer's & Dementia - Wiley Online Library https://t.co/8ZTxhhCn66
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
RT @daperezm: Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheim…
Análisis crítico de la posible autorización de Aducanumab en el tratamiento de la Enf. Alzheimer por David Knopman en Alzheimer´s & Dementia
Superpolémica con el medicamento aducanumab, que según la farmaceútica tiene efectos sobre el alzheimer, mientras que otros análisis dicen que esos efectos no son robustos. Preocupa el alto precio. Esta semana es clave ya que podría ser aprobada por la FDA https://t.co/BRRFRwrrI1
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @brainoscience: A pretty comprehensive review of the #aducanumab data publicly available so far by David Knopman M.D. ahead of the FDA's…
A pretty comprehensive review of the #aducanumab data publicly available so far by David Knopman M.D. ahead of the FDA's review this week. #Alzheimers #Biogen https://t.co/tvelNxmuz8
RT @M_SuarezCalvet: The case for efficacy of #Aducanumab in #Alzheimer - a highly recommended discussion on this complex issue in @alzassoc…
RT @CNC_Alzheimer: Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen. The la…
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen. The larger decline in the placebo group in EMERGE is an alternative explanation for statistically significant benefits for high‐dose ADU. https://t.co/RTREvROUxw
$BIIB Dr. Knopman rescued himself from PCNS panel & stating against adu's case through pub - "Failure to demonstrate efficacy for aducanumab" https://t.co/oPsKcmpTKL To draw parallel, below in 2016 panelists for SRPT eteplirsen DMD voted 7-3 against its approval https://t.co/r2A6go5E8y
"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen" (A&D 2020) - "Recent experience with solanezumab should be a cautionary reminder of the fickleness of claims based on post hoc analyses" - https://t.co/BAkDTaiiVA https://t.co/WVjp649hVn
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
Buckle up! https://t.co/O9GTVADzqt
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
Ever wondered what highly respected #Alzheimer clinical researchers think about #Aducanumab? Good enough to grant #FDA approval ?? - read Dr. David Knopman's resounding "no" in https://t.co/huZTPDIFYY.
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @michaelscally: Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, Decemb…
RT @michaelscally: Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, Decemb…
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 https://t.co/sgnoQKsfON
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
The case for efficacy of #Aducanumab in #Alzheimer - a highly recommended discussion on this complex issue in @alzassociation https://t.co/Au4cZop6Ni
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @DavidJonesBrain: Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devas…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
RT @adamfeuerstein: $BIIB - Newly published paper in Azheimer’s & Demential, written by three neurologists says aducanumab should not be ap…
Aducanumab is up for review by the FDA for Alzheimer’s. We all are heartbroken with the lack of progress on this devastating disease. #ENDALZ See our dispassionate assessment of the data in this perspective: “Failure to demonstrate efficacy of aducanumab” https://t.co/CSWR7PB1yO
EZ
DJ
DM
FD
青発
MU
KS
J
NP
YV
G
I
DZ
M
L
AP
E
さ
医
松M
BP
CM
AP
JL
A
E
ハZ
DB
N脳
か
JF
S
TD
N
D
な
忍
VH
SE
S
BH
C
DV
ゆ
か
イ
FL
DP
A
BE
EM
WN
E
DB
EB
IM
SL
H
N
PL
LJ
J
ZO
BS
SA
ME
JG
NC
MF
M
DS
A
PR
RP
DH
PC
HD
MP
SC
FF
C
U
ÁS
UD
?
AP
WF
B
LV
C
CC
PS
JD
LF
B
JS
B
MN
GK
SL
PC
SO
DG
M
BT
WP
NG
L
WH
FP
HZ
RD
RS
AG
AL
BS
R
MC
VP
SB
MC
TB
W
BS